Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

Signal transducers and activators of transcription 3 (STAT3) is constitutively active in human pancreatic cancer cells and can promote cell growth and apoptosis resistance that contribute to tumorigenesis. We determined if sorafenib, a multikinase inhibitor, can induce apoptosis by targeting STAT3 signaling to enhance apoptosis induction by tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). Human pancreatic cancer cell lines (PANC-1 and BxPC-3) were preincubated with sorafenib (Nexavar) alone or followed by TRAIL. Apoptosis was determined by Annexin V labeling, caspase cleavage, and Bax/Bak activation. Protein expression was analyzed by immunoblotting. Knockdown of STAT3, Mcl-1, and Bim were achieved by lentiviral small hairpin RNA. Adenoviral dominant-negative or retroviral constitutively active (CA) STAT3 were also used. Sorafenib inhibited constitutive STAT3 phosphorylation (Tyr705) and suppressed Mcl-1 and Bcl-xL proteins in a dose- and time-dependent manner. CA-STAT3 overexpression was shown to attenuate caspase-3 cleavage and suppression of Mcl-1 by sorafenib. STAT3 knockdown or a DN STAT3 was shown to downregulate Mcl-1 and Bcl-xL and to sensitize cells to TRAIL-mediated apoptosis. Treatment with sorafenib enhanced TRAIL-induced Annexin V staining and release of mitochondrial cytochrome c and AIF. Because the BH3-only Bim protein is a potent inducer of mitochondrial apoptosis, Bim knockdown was shown to attenuate caspase-3, caspase-9 cleavage, and Bax/Bak activation by sorafenib plus TRAIL. The suppression of STAT3 by genetic means or using sorafenib was shown to downregulate Mcl-1 and Bcl-xL and to sensitize cells to TRAIL-mediated apoptosis. These data indicate that targeting STAT3 may enhance treatment efficacy against pancreatic cancer. Mol Cancer Ther; 9(3); 742–50

[1]  G. Gores,et al.  Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 , 2009, Hepatology.

[2]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[3]  F. Sinicrope,et al.  BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells , 2009, Clinical Cancer Research.

[4]  R. Jove,et al.  Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas , 2008, Molecular Cancer Therapeutics.

[5]  S. Belinsky,et al.  Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells , 2008, Molecular Cancer Therapeutics.

[6]  F. Sinicrope,et al.  BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. , 2008, Cancer research.

[7]  W. El-Deiry,et al.  Mcl-1: a gateway to TRAIL sensitization. , 2008, Cancer research.

[8]  L. Lang.  FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[9]  M. Konopleva,et al.  Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway , 2008, Leukemia.

[10]  T. Uchida,et al.  Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity , 2007, Oncogene.

[11]  David Loegering,et al.  MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis , 2007, Journal of Biological Chemistry.

[12]  Jorge A. Almenara,et al.  The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. , 2007, Cancer research.

[13]  K. Flaherty,et al.  Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.

[14]  S. Fesik,et al.  ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 , 2007, Oncogene.

[15]  Ronald Koschny,et al.  The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.

[16]  G. Cooper,et al.  Rapid Turnover of Mcl-1 Couples Translation to Cell Survival and Apoptosis* , 2007, Journal of Biological Chemistry.

[17]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[18]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[19]  R. Pazdur,et al.  Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[20]  R. Kurzrock,et al.  Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells , 2006, Molecular Cancer Therapeutics.

[21]  John C Reed,et al.  Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms , 2006, Nature Clinical Practice Oncology.

[22]  B. Gastman,et al.  Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis* , 2006, Journal of Biological Chemistry.

[23]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[24]  P. Dent,et al.  Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.

[25]  G. Gores,et al.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.

[26]  L. Behrend,et al.  Manganese Superoxide Dismutase Induces p53-Dependent Senescence in Colorectal Cancer Cells , 2005, Molecular and Cellular Biology.

[27]  L. Ellis,et al.  HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas , 2005, Oncogene.

[28]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[29]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[30]  F. Sinicrope,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells , 2004, Clinical Cancer Research.

[31]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[32]  K. Podar,et al.  Mcl-1 Regulation and Its Role in Multiple Myeloma , 2004, Cell cycle.

[33]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[34]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[35]  B. Wiedenmann,et al.  Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. , 2003, Gastroenterology.

[36]  S. Korsmeyer,et al.  VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis , 2003, Science.

[37]  J. Abbruzzese,et al.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.

[38]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[39]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[41]  G. Wu,et al.  Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[42]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[44]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[45]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[46]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[47]  H. Obata,et al.  Frequency and Types of Point Mutation at the 12th Codon of the c‐Ki‐ras Gene Found in Pancreatic Cancers from Japanese Patients , 1989, Japanese journal of cancer research : Gann.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.